Information Provided By:
Fly News Breaks for September 13, 2019
FCSC
Sep 13, 2019 | 09:41 EDT
H.C. Wainwright analyst Joseph Pantginis downgraded Fibrocell Science to Neutral from Buy after the company announced that it was being acquired by FCX-007's development and commercialization partner, Castle Creek Pharmaceuticals, for $3 per share in cash. He lowered his price target on the stock to $3 from $20 to reflect the terms of the deal.
News For FCSC From the Last 2 Days
There are no results for your query FCSC